Shares of Neurogene Inc. (NASDAQ:NGNE – Get Free Report) have been assigned an average rating of “Buy” from the nine analysts that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $51.00.
Several equities research analysts have issued reports on the stock. Baird R W raised shares of Neurogene to a “strong-buy” rating in a research report on Tuesday, June 11th. Robert W. Baird began coverage on Neurogene in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $54.00 price objective on the stock. BMO Capital Markets started coverage on Neurogene in a report on Thursday, June 27th. They set an “outperform” rating and a $65.00 price objective on the stock. Finally, HC Wainwright lowered their target price on Neurogene from $51.00 to $49.00 and set a “buy” rating for the company in a report on Monday, August 12th.
Read Our Latest Research Report on Neurogene
Hedge Funds Weigh In On Neurogene
Neurogene Trading Up 4.5 %
Shares of NASDAQ NGNE opened at $41.75 on Friday. Neurogene has a fifty-two week low of $12.49 and a fifty-two week high of $53.00. The business’s 50 day moving average price is $38.10 and its 200-day moving average price is $37.75.
Neurogene (NASDAQ:NGNE – Get Free Report) last released its earnings results on Friday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.07). The firm had revenue of $0.93 million during the quarter. Analysts forecast that Neurogene will post -4.47 earnings per share for the current year.
Neurogene Company Profile
Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Featured Stories
- Five stocks we like better than Neurogene
- How to Invest in Blue Chip Stocks
- S&P 500 Hitting Resistance: These 3 Stocks Offer the Best Upside
- 10 Best Airline Stocks to Buy
- Nike’s Post-Earnings Drop Presents a Buying Opportunity
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Microsoft’s Targeted Upside Might Be Too Good to Ignore
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.